Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based Founder operating in the Health Diagnostics space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Robert Nelsen
Co-Founder & Managing Director of ARCH Venture Partners
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Unity Biotechnology (UBX); Sienna Biopharmaceuticals (SNNA); Vir Biotechnology, Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL, Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics, KSQ Therapeutics, Beam Therapeutics, NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT), IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); WuxiNextCODE; and Everyday Learning Corporation. Mr. Nelsen is a director of Vir Bio, GRAIL, Sienna Biopharmaceuticals, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
Follow Robert Nelsen:
About ARCH Venture Partners: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
_______
Keith Crandell
Founder and Managing Director of ARCH Venture Partners
Keith L. Crandell is the Co – Founder & Managing Director, ARCH Venture Partners. He focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory. Mr. Crandell has played a key role in the formation and initial funding round of Quanterix, Alfalight, PixelEXX Systems, ALIS Corp. (acquired by Carl Zeiss SMT), Eichrom Industries (acquired by Gary Comer, Inc.), Nanophase Technologies (NANX), and Illinois Superconductor. He was also responsible for ARCH’s investment in New Era of Networks (NEON, acquired by Sybase-SY), Apropos Technology (APRS, acquired by Syntellect-ESL), Teach.com (acquired by Intellinex), CelebrateExpress (BDAY, acquired by Liberty Media-LINTA), Ahura Scientific (acquired by Thermo Fisher Scientific-TMO), Adesto Technologies, Ciespace, Boreal Genomics, and Crystal IS (acquired by Asahi Kasei-AHKSY), among others. He is a Director of Quanterix, Nanosys, Alfalight, Adesto Technologies, Boreal Genomics, PixelEXX Systems, Univa, Ciespace. Mr. Crandell also serves as a Director of the Illinois Venture Capital Association. Prior to the founding of ARCH, Mr. Crandell was with the specialty chemical and polymer company, Hercules, Inc. He holds an M.B.A. from The University of Chicago. An M.S. in Chemistry from the University of Texas at Arlington. B.S. in Chemistry and Mathematics from St. Lawrence University.
Follow Keith Crandell:
About ARCH Venture Partners: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Clinton Bybee
Co-Founder and Managing Director of ARCH Venture Partners
Clinton Bybee is a co-founder and Managing Director of ARCH Venture Partners. Mr. Bybee concentrates primarily on advanced materials, electronics, semiconductors, photonics, and infrastructure businesses. Mr. Bybee has helped organize and finance numerous companies including MicroOptical Devices (acquired by EMCORE), Cambrios Technologies, Aveso, Innovalight, Intelligent Reasoning Systems (acquired by Photon Dynamics), Semprius, Nanosys, and Xtera Communications. He is a board member of Impinj, Innovalight, Cambrios Technologies, Xtera Communications, Nitronex and Aveso. Mr. Bybee is an organizing member of the Texas Venture Capital Association and currently serves as its first President. Previously, Mr. Bybee worked with ARCH Development Corporation. He also managed a venture investment fund for the State of Illinois and was a production engineer with Amoco Corporation.
Follow Clinton Bybee:
About ARCH Development Corporation, ARCH Venture Partners, Nitronex: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Adam Karp
Co-Founder & CEO of Lively
Prior to Lively, Adam was the Chief Marketing Officer of 1stdibs – the world’s premier destination for unique, luxury design. At 1stdibs, Adam was instrumental in increasing the company’s revenue almost 10x; recruited and led a team of 100 and had full P&L responsibility for 1stdibs’ B2B business. Before 1stdibs Adam worked in senior roles at leading brands such as FreshDirect, Barnes & Noble and Century 21 real estate. At Century 21 he was responsible for developing and launching Century 21’s first website which at the time became the most recognized real estate website in the country and currently generates almost 50 million visits a year. After Century 21, Adam spent almost a decade at Barnes & Noble in increasingly senior roles ultimately becoming VP of Direct Marketing for both the retail stores and online. At Barnes & Noble, Adam managed some of the largest digital marketing programs in the industry, overseeing a budget of $100M. Adam graduated from the The Wharton School at the University of Pennsylvania with a degree in Economics.
Follow Adam Karp:
About Lively: Lively’s mission is to democratize, simplify and de-stigmatize the adoption and use of technically advanced hearing aids.
Elad Kolet
Co-Founder & CTO of Lively
Elad is a technology leader with more than 15 years of experience in software engineering. Most recently Elad ran the North America Solutions Engineering team at Facebook where he managed a team of 32 full-stack engineers responsible for building Facebook’s advertising products. Prior to working at Facebook, Elad worked as an Engineering Lead at Microsoft, driving the development of Windows Azure. Before Microsoft, Elad was a Senior Software Engineer at RiT technologies LTD., where he designed and built network products used by large corporate clients including Goldman Sachs UK and Morgan Stanley UK. Elad was raised in Israel and spent four years as a software engineer in the Israeli Intelligence Corps’ Unit 8200, an incubator of tech talent whose alumni have gone on to found numerous technology companies. Elad earned his BS in Computer Science from the Academic College of Tel-Aviv, Yaffo.
Follow Elad Kolet:
About Lively: Lively’s mission is to democratize, simplify and de-stigmatize the adoption and use of technically advanced hearing aids.
David Rust
Co-Founder & Advisor of Lively
David is a seasoned operator who helped scale Lyft from 25 to 1,600 employees and an $11B+ valuation. He launched Lyft’s first markets across the US and translated these learnings into the company’s national expansion playbook. David then went on to build and lead Lyft’s internal strategy team, reporting to Lyft’s COO. This team was responsible for leading high-priority strategic initiatives, from Lyft’s partnership with General Motors to its first self-driving car implementations. Prior to Lyft, David led market expansion and local marketing for one of the early pioneers in the car sharing industry, Wheelz, which was acquired by RelayRides (not Turo). David graduated from Stanford University with a degree in Environmental Engineering and was named as a member of the Forbes 30 Under 30 class of 2017.
Follow David Rust:
About Lively: Lively’s mission is to democratize, simplify and de-stigmatize the adoption and use of technically advanced hearing aids.
Jennifer Doudna
Co-Founder of Mammoth Biosciences
As an internationally renowned professor of Chemistry and Molecular and Cell Biology at U.C. Berkeley, Dr. Jennifer Doudna and her colleagues rocked the research world in 2012 by describing a simple way of editing the DNA of any organism using an RNA-guided protein found in bacteria. This technology, called CRISPR-Cas9, has opened the floodgates of possibility for human and non-human applications of gene editing, including assisting researchers in the fight against HIV, sickle cell disease and muscular dystrophy. Doudna is an investigator with the Howard Hughes Medical Institute, senior investigator at Gladstone Institutes, and the Executive Director of the Innovative Genomics Institute. She is a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, and the American Academy of Arts and Sciences. Doudna is also a Foreign Member of the Royal Society and has received numerous other honors including the Breakthrough Prize in Life Sciences, the Japan Prize, and the Kavli Prize. Doudna’s work led TIME to recognize her as one of the “100 Most Influential People” in 2015, and she is the co-author of “A Crack in Creation,” a personal account of her research and the societal and ethical implications of gene editing. She is a vocal proponent of its responsible use, first calling for a moratorium on using CRISPR technology to make permanent changes to the human germline in 2015.
Follow Jennifer Doudna:
About Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Mammoth Biosciences, Scribe Therapeutics, University of California Berkeley: Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
Trevor Martin
Co-Founder and CEO of Mammoth Biosciences
As co-founder and CEO of Mammoth Biosciences, Trevor Martin is focused on creating the world’s first CRISPR-based platform for disease detection, taking impactful CRISPR technology out of the lab and into the hands of doctors and consumers. Prior to co-founding Mammoth, Trevor completed his PhD in Biology at Stanford University, where he worked at the intersection of statistics and genetics. In addition to having taught a course in Statistics at Stanford, Trevor has penned educational guides for university courses across the globe. His work has been featured in outlets like FiveThirtyEight and The Atlantic.
Follow Trevor Martin:
About Mammoth Biosciences: Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
Yury Yakubchyk
Founder of Elemy
Yury Yakubchyk is the Founder of Sprout Therapy. He is also the Chief Technology Officer at Life House, where he manages the technology, growth marketing, data analytics, and digital design teams. Yury is responsible for Life House’s unique digital strategy. Previously, Yury was a Chief Technology Officer at New York-based Wing (wingalpha.com, Wing Tel, and Wing Call on the Apple App Store), a modern millennial-tailored mobile virtual network operator selling custom cellular subscription plans and mobile devices on the Sprint network. The wing is venture-backed by several prominent venture capital firms and angel investors. Prior to Wing, Yury worked in the financial services industry. Yury is a self-taught programmer and digital product designer as well as a graduate of the Johns Hopkins University, where he was a Woodrow Wilson Fellow. Yury is originally from New York City.
Follow Yury Yakubchyk:
About Cold Start Ventures, Elemy, Life House, Wing Tel, Inc.: Elemy is a B2B2C platform helping provide access to in-home pediatric care for ongoing behavioral challenges, including autism.
Zachariah Reitano
Co-Founder and CEO of Ro
Zachariah is the CEO and cofounder of Ro. Founded in 2017, Ro is a healthcare technology company with a mission to provide personalized healthcare to everyone on the planet. Ro has three end-to-end verticals: Roman (men’s health), Rory (women’s health), and Zero (fighting addiction). As CEO and cofounder, Zachariah leads all medical and regulatory operations and oversees all verticals. Zachariah was named Inc. Magazine’s 30 Under 30, Business Insider’s 30 Under 40 in Healthcare, and a finalist in EY’s Entrepreneur of the Year. Ro was named #2 in Wellness in Fast Company’s World’s Most Innovative Companies 2019.
Follow Zachariah Reitano:
About Ro, Roman: Ro is a telehealth startup that operates digital health clinics for men’s and women’s health, along with smoking cessation.
Rob Schutz
Co-Founder, Chief Growth Officer of Ro
Rob Schutz is a Co-Founder at Ro.
Follow Rob Schutz:
About BarkBox, Ro, Roman: Ro is a telehealth startup that operates digital health clinics for men’s and women’s health, along with smoking cessation.
Saman Rahmanian
Co-Founder, Chief Product Officer of Ro
Saman Rahmanian is the co-founder of Ro, a mission-driven healthcare technology company, and Managed by Q, the smart office management company. Saman also holds a partner role at Prehype, a venture development firm that incubates new businesses together with large corporations. Before Prehype, Saman started his career in advertising agencies around the world, where he became the 5th most awarded creative around the globe.
Follow Saman Rahmanian:
About Ro, Roman: Ro is a telehealth startup that operates digital health clinics for men’s and women’s health, along with smoking cessation.
Mitchell Rales
Co-Founder of Danaher
Mitchell Rales is a co-founder of Danaher and has served on Danaher’s Board of Directors since 1983, serving as Chairman of the Executive Committee of Danaher since 1984. He was also President of Danaher from 1984 to 1990. In addition, for more than the past five years he has been a principal in private and public business entities in the manufacturing area. Mitchell is a member of the board of directors of Colfax Corporation, and is a brother of Steven Rales. The strategic vision and leadership of Mitchell and his brother, Steven Rales, helped create the Danaher Business System and have guided Danaher down a path of consistent, profitable growth that continues today. In addition, as a result of his substantial ownership stake in Danaher, he is well-positioned to understand, articulate and advocate for the rights and interests of Danaher’s shareholders.
Follow Mitchell Rales:
About Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Steven Rales
Co-Founder of Danaher
Steven Rales is a co-founder of Danaher and has served on Danaher’s Board of Directors since 1983, serving as Danaher’s Chairman of the Board since 1984. He was also CEO of Danaher from 1984 to 1990. In addition, for more than the past five years he has been a principal in private business entities in the area film production. Steven is a brother of Mitchell Rales. The strategic vision and leadership of Steven and his brother, Mitchell Rales, helped create the Danaher Business System and have guided Danaher down a path of consistent, profitable growth that continues today. In addition, as a result of his substantial ownership stake in Danaher, he is well-positioned to understand, articulate and advocate for the rights and interests of Danaher’s shareholders.
Follow Steven Rales:
About Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Daniel Rotman
Founder & CEO of PrettyLitter
Harvard University’s Center for Public Leadership Fellow. Founder and CEO of PrettyLitter.
Follow Daniel Rotman:
About PrettyLitter: PrettyLitter’s lightweight litter monitors feline health by changing colors when it detects potential issues through your cat’s urine.
Sam Santhosh
Founder Chairman & Global CEO of MedGenome
Sam Santhosh is the Founder and CEO of MedGenome. He has been an entrepreneur, with over 20 years of experience in the software industry. Currently, he is at the helm of affairs as CEO and promoter of MedGenome Labs Pvt Ltd. Sam sits on the board of a number of companies, both in the US and India. In this role he advises, guides and mentors companies to help them grow and realize their true potential. Prior to this Sam was the CEO and Managing Director of California Software Limited (Calsoft) from 1992 – Feb 2012. He founded Calsoft in 1992 and under Sam’s vision, Calsoft rapidly grew from a niche player in the Silicon Valley to a global player with over 1200 employees and presence in 8 countries. Sam took Calsoft Public and the company is listed the in Indian Stock Exchanges. Sam oversaw the growth of Calsoft in all key areas – Finance, Strategy, Customer Acquisition, and inorganic growth through eight acquisitions including companies in the U.S, UK, Japan, and India. He has been constantly retooling himself and has attended various training programs in different U.S universities including MIT. In 2010, he completed the Executive Education program at the Singularity University in Sunnyvale, California. Sam has an engineering degree and an MBA (majoring in Management Information Systems) from India’s premier institute, IIM Calcutta.
Follow Sam Santhosh:
About Agrigenome, MedGenome: MedGenome develops a genomics-based diagnostics and research solution for healthcare providers to understand the genetic basis of diseases.
Sylvana Quader Sinha
Founder, Managing Director and CEO of Praava Health
Sylvana Q. Sinha is founder and CEO of Praava Health, a leading healthcare company focused on improving health outcomes and patient journeys in emerging markets, where 85% of the world lives but whose current systems typically prioritize profits over patients.
Since launching in 2018, Praava has become Bangladesh’s fastest-growing consumer healthcare brand, and was designated a 2021 World Economic Forum Technology Pioneer and 2020 Fast Company World Changing Idea and Developing World Technology. Praava has served more than 300,000 patients and is tripling growth each year. Throughout the COVID-19 pandemic, Praava quadrupled its patient base while maintaining an NPS rating of 91.3—significantly exceeding even the highest scores of Fortune 500 companies.
Sylvana also has decades of experience leading teams in international law, business, development, and government relations at major international law firms, management consulting firms, the World Bank, and think tanks in the Middle East and S. Asia. In addition to serving as an advisor to then-Senator Obama, she has independently advised private and sovereign clients on investments, projects, and disputes in the Middle East, Africa, and S. Asia.
Sylvana is a Life Member of the Council on Foreign Relations, a member of the World Economic Forum’s UHC2030 Private Sector Constituency, and served on Mount Sinai’s Arnold Institute of Global Health Task Force for Global Advantage. She is a graduate of Columbia Law School, Harvard’s Kennedy School, and Wellesley College and was a Visiting Scholar at the University of Oxford.
Follow Sylvana Quader Sinha:
About Praava Health: Praava Health is a patient-driven company disrupting the healthcare standard for Bangladesh’s 170 million citizens.
David Yu Zhang
Co-Founder & Head of Innovation of NuProbe
David Zhang, Ph.D., is the Ted Law Jr. Assistant Professor of Bioengineering at Rice University. He is a leading expert in molecular diagnostics and DNA biotechnology, and maintains active collaborations with multiple biotech companies.
Follow David Yu Zhang:
About NuProbe: An early stage molecular diagnostics company.
Peng Yin
Co-Founder, Director of NuProbe
Peng is a Professor in the Department of Systems Biology at Harvard Medical School. He also serves as a Core Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he co-founded Ultivue. Co-Founder, Director at Torus Biosystems.
Follow Peng Yin:
About Harvard Medical School, NuProbe, Torus Biosystems, Ultivue, Wyss Institute: An early stage molecular diagnostics company.
Yingshuang Chai
Co-Founder & CEO of NuProbe
Yingshuang Chai is a Co-Founder, CEO, and Chairman of the Board of Directors at NuProbe.
Follow Yingshuang Chai:
About NuProbe: An early stage molecular diagnostics company.
Junfeng Luo
Co-Founder & Vice President, R&D – NuProbe, China of NuProbe
Junfeng Luo is a Co-Founder and Vice President of R&D at NuProbe, China.
Follow Junfeng Luo:
About NuProbe: An early stage molecular diagnostics company.
Yundi Chen
Co-Founder of NuProbe
Yundi Chen is a Co-Founder at NuProbe.
Follow Yundi Chen:
About NuProbe: An early stage molecular diagnostics company.
Mike McSherry
CEO & Founder of Xealth
CEO at Xealth.
Follow Mike McSherry:
About Xealth: Xealth is a platform for digital health, enabling clinicians to prescribe and monitor digital tools from within the EHR workflow.
Eric Fu
Co-Founder and CTO of Xealth
Eric Fu is Co-d=founder and Chief Technology Officer at Xealth. Before this, he was with Providence Health & Services as resident entrepreneur. He was director of engineering at Nuance Communications as well.
Follow Eric Fu:
About Xealth: Xealth is a platform for digital health, enabling clinicians to prescribe and monitor digital tools from within the EHR workflow.
Roy Paxton Yih
Co-Founder and CEO of Biocare Medical
Roy Paxton Yih, BS, MA, co-founded Biocare Medical, LLC in 1997 and serves as its Chief Executive Officer and President. Roy Yih served as a Director of Sales & Marketing at Biocare Medical LLC. Roy Yih is primarily involved at sales, marketing and business development activities. He holds a BS Degree in Biochemistry from U.C. Davis and an MBA from the University of Santa Clara.
Follow Roy Paxton Yih:
About Biocare Medical: Biocare Medical is a provider of immunohistochemistry instrumentation.
Chris Mansi
CEO, Co-Founder of Viz
Dr Mansi is a former Neurosurgeon and the CEO of Viz.ai an Applied AI Healthcare company.They recently received FDA clearance for the first ever AI aided triage and notification platform, opening the door to AI in acute emergency healthcare. Chris is a clinician innovator, entrepreneur and optimist focused on increasing healthcare access, building and supporting great teams and improving provider experience. Viz.ai builds clinician facing products that enable and empower doctors, allowing them to provide the best care to patients, everytime, everywhere.
Follow Chris Mansi:
About Viz: Viz is a medical imaging company that helps optimize emergency treatment using deep learning technology.
John Fontein
Co-Founder of Sesame
John Fontein is Co-Founder and President at Sesame. Previously, he was the VP of Business Development at GoEuro where he oversaw all revenue functions including sales, marketing and partnerships. John began his career at Goldman Sachs where he worked in both the Investment Banking and Investment Management Divisions of the firm. John is a multi-platinum song-writer, producer, and sound designer. He is the recipient of numerous awards including an MTV Video Music Award, a Berklee Jazz Festival Award and a FringeNYC Award. John attended Saint Ann’s School in Brooklyn and graduated summa cum laude from Princeton University with a B.A. in Music and a certificate in Computer Science.
Follow John Fontein:
About Sesame: Sesame is a healthcare superstore, with over 10,000 medical practices offering affordable prices for care in-person or online.
David Goldhill
Co-Founder & CEO of Sesame
David Goldhill is the founder and CEO of Sesame.
Follow David Goldhill:
About Game Show Network, Sesame: Sesame is a healthcare superstore, with over 10,000 medical practices offering affordable prices for care in-person or online.
Charles Roberts
Co-Founder, Chief Growth Officer of Freenome
A clinician by training, Charlie is Freenome’s Chief Partnership Officer, focusing on mid- and longer-term relationships that will help define the company’s future directions and revenues and works closely with the business development team in managing corporate client accounts and institutional collaborations. Prior to co-founding Freenome, Charlie co-founded a company that uses circulating cell-free (cf)DNA from maternal blood samples to diagnose chromosomal abnormalities during pregnancy. The resulting in-vitro diagnostic, IONA, has been marketed successfully across Europe and the Middle East. Charlie studied medicine and neuropsychology in the UK, earning a Masters degree from Oxford with a focus on immunotherapy. He has worked in some of the UK’s leading oncology centers, including the Royal Marsden.
Follow Charles Roberts:
About Freenome, Relation Therapeutics: Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Riley Ennis
Co-Founder and COO of Freenome
Riley is a Thiel Fellow who created a cancer vaccine with his previous company Immudicon as Co-Founder & Chair. Co-Founder, COO at Freenome.
Follow Riley Ennis:
About Freenome, Immudicon, Oncolinx, The Thiel Foundation: Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Philip Fung
Founder / CEO of Kit.com
Founder/CEO @Kit.com, Engineer #15 @Facebook
Follow Philip Fung:
About Kit.com: Kit.com is a home medical exams, delivered. Kit makes health testing simpler, easier and more reliable for your patients.
Drew Perkins
Co-Founder and CEO of Mojo Vision
Follow Drew Perkins:
About Mojo Vision: Mojo Vision is developing Mojo Lens, the world’s first AR smart contact lens with a built-in display that delivers Invisible Computing
Michael Wiemer
VP Eng / Co-Founder and CTO of Mojo Vision
Michael Wiemer is the Co-Founder and CTO at Mojo Vision.
Follow Michael Wiemer:
About Mojo Vision: Mojo Vision is developing Mojo Lens, the world’s first AR smart contact lens with a built-in display that delivers Invisible Computing
Pranay Kapadia
Co-Founder & CEO of Notable
Pranay Kapadia is a VP of Product at Blend Labs.
Follow Pranay Kapadia:
About Notable: Notable is an AI-powered health start-up that automates and digitizes every physician-patient interaction.
Adam Ting
Co-Founder & CPO of Notable
Follow Adam Ting:
About Notable: Notable is an AI-powered health start-up that automates and digitizes every physician-patient interaction.
Justin White
CTO and Co-Founder of Notable
Justine White is the Co-Founder & CTO at Notable.
Follow Justin White:
About Notable: Notable is an AI-powered health start-up that automates and digitizes every physician-patient interaction.
Maria Artunduaga
Founder and CEO of Respira Labs
Follow Maria Artunduaga:
About Respira Labs: Respira Labs is building an AI-powered sensor platform to track, predict, and prevent chronic lung disease.
Boris Lipchin
Founder and CEO of BRIO Systems
Boris Lipchin, co-founder and CEO of Brio Systems, Inc.. Boris was previously a co-founder and CTO of Airmada, Inc. before Airmada four years as a flight software engineer, launch operator and GN&C engineer for SpaceX.
Follow Boris Lipchin:
About Brio, BRIO Systems, Techstars: BRIO Systems offers a complete COVID-19 testing system to help employers keep teams safe and businesses on track.
Frank Lee
CEO & Founder of Virus Geeks Inc.
Follow Frank Lee:
About CarSnatch, Virus Geeks Inc.: SaaS, Mobile App, BioHealth, Information Technology
Hesaam Esfandyarpour
Founder and CEO of Genapsys
Hesaam is the Founder and CEO of GenapSys Inc. He is an inventor of electronic DNA sequencing, a technology he developed during his PhD work at Stanford. Hesaam has dedicated the past decade of his life to the development of this novel DNA sequencing technology, which has at its core the convergence of multiple fields of science – engineering, chemistry, biology, and computing. Hesaam incubated the technology at the Stanford Genome Technology Center for a period of six years before securing licenses to the IP and incorporating GenapSys in January of 2010. He has grown GenapSys from just a handful of employees working out of Menlo Labs incubator space, to over 50 employees across seven functional teams. In 2012, Hesaam partnered GenapSys with StartX, an accelerator for the development of Stanford’s top entrepreneurs. He has raised approximately $50M for GenapSys in Seed, Series A, and Series B rounds of financing. Hesaam holds a PhD and MS in Electrical Engineering, and MSc Management degree, all from Stanford University. He earned his BS in Electrical Engineering with Honors from Sharif University of Technology in Tehran, Iran. When he is not at GenapSys HQ (which is rare!) you can find Hesaam spending time outdoors, hiking or spending time with family and friends. He is also a great lover of poetry, his favorite of which are poems by the Persian poet Saa’di.
Follow Hesaam Esfandyarpour:
About Genapsys: Transform the human condition by building a scalable, affordable genomic sequencing ecosystem that will support research and diagnostics
Oguzhan Atay
Co-Founder of BillionToOne
Oguzhan is responsible for implementing BillionToOne’s vision and for all day-to-day management decisions. During his PhD at Stanford, he has combined machine learning and genetics to solve problems in cell biology. His PhD research has been featured as Cover Article in Cell Systems, and his work has been published in high-impact peer-reviewed journals, including Cell and Journal of Cell Biology.
Follow Oguzhan Atay:
About BillionToOne: BillionToOne is a precision diagnostics company that makes molecular diagnostics accurate, efficient, and accessible for all.
Johannes Fruehauf
Founder, President & Executive Director of LabCentral
Johannes Fruehauf is the Founder & CEO LabCentral/Biolabs.He is responsible for all aspects of LabCentral’s operation. Johannes is a physician and successful biotech entrepreneur. Prior to LabCentral, he founded Cambridge Biolabs, a contract research facility serving startup and virtual companies in Kendall Square. He is also a co-founder of ViThera Pharmaceuticals, Deltix and Cequent Pharmaceuticals, and an advisor or board member to numerous life sciences companies and non-profits. Johannes earned his medical degree at the University of Frankfurt and his PhD at the University of Heidelberg (Germany).
Follow Johannes Fruehauf:
About Arkuda Therapeutics, BioLabs, Cequent Pharmaceuticals, Deltix, LabCentral, Mission BioCapital: LabCentral developing novel cancer treatments: Conkwest, Inc, headquartered in DelMar, California, is opening its research laboratory at
Marc Korczykowski
CEO and Co-Founder of Hura Imaging
Marc Korczykowski is Hura Imaging’s Co-Founder and CEO.
Follow Marc Korczykowski:
About Hura Imaging: Hura Imaging develops and commercializes novel CT technology that decreases radiation dose significantly in patient management.
Danny JJ Wang
CSO and Co-Founder of Hura Imaging
Danny JJ Wang is the Co-Founder and Chief Science Officer of Hura Imaging.
Follow Danny JJ Wang:
About Hura Imaging: Hura Imaging develops and commercializes novel CT technology that decreases radiation dose significantly in patient management.
Aditya Rajagopal
Co-Founder & CTO of ChromaCode
Aditya Rajagopal is the Founder & CTO of ChromaCode, Inc, and a Visiting Associate in Electrical Engineering at Caltech. He completed his education at Caltech (B.S., M.S., and Ph.D.) and has fifteen years of experience in medical engineering, microfluidics, nanotechnology and bioengineering. Aditya Rajagopal’s research has resulted in innovative technology developments and he has authored over 50 patents and publications. He is the recipient of numerous honors including the Caltech Grubstake Award in 2017 and the Caltech Innovation Initiative (CI2) in 2014 and 2015.
Follow Aditya Rajagopal:
About ChromaCode: ChromaCode is a molecular diagnostics company focusing on bioinformatics.
Greg Gosch
Co-Founder, President, & CEO of ChromaCode
Greg has over 20 years of management experience in the molecular diagnostics and nucleic acids research fields. He spent 9 years at Luminex, when the company grew revenues from $30 million to over $200 million. He held multiple roles including VP of Sales and Marketing, where he was responsible for global commercial operations, and VP/GM of Biosciences, where was responsible for developing novel instrument and assay products for gene expression, microRNA, newborn screening and Alzheimer’s disease. Prior to Luminex, Greg served in various commercial leadership roles at Nanogen, Chiron Diagnostics and Bio-Rad. He has a bachelors degree in molecular, cellular and developmental biology from the University of Colorado and dual masters degrees in business and healthcare administration from the University of Minnesota.
Follow Greg Gosch:
About ChromaCode: ChromaCode is a molecular diagnostics company focusing on bioinformatics.
Axel Scherer
Co-Founder of ChromaCode
Axel is a ChromaCode founder and the Bernard A. Neches Professor of Electrical Engineering, Applied Physics and Physics at Caltech. He joined the Electrical Engineering department at Caltech in 1993, after working in the Microstructures Research Group at Bellcore. Axel’s group works on micro- and nanofabrication of optical, magnetic and fluidic devices. He has co-authored over 300 publications and holds over 70 patents in the fields of optoelectronics, microfluidics, and new nanofabrication techniques. Axel has co-founded three high-technology companies and built a state of the art laboratory for advanced high-resolution lithography and pattern transfer at Caltech. He has pioneered microcavity lasers such as vertical cavity surface emitting lasers, microdisk lasers and photonic crystal lasers in many materials systems. Presently, his group works on integration of microfluidic chips with electronic, photonic and magnetic sensors. His group has also developed silicon nanophotonics and surface plasmon enhanced light emitting diodes, and has perfected the fabrication and characterization of ultra-small structures by lithography and electron microscopy. He received hi PhD in 1985 from the New Mexico Institute of Mining and Technology.
Follow Axel Scherer:
About ChromaCode: ChromaCode is a molecular diagnostics company focusing on bioinformatics.
Sasan Amini
Co-Founder and CEO of Clear Labs
Sasan combined his academic expertise and passion for healthy living when he co-founded Clear Labs with a mission to set a new paradigm for food safety and quality. Prior to serving as the CEO of Clear Labs, he worked in the Advanced Research department at Illumina. Sasan earned his PhD in Genomics from Princeton and holds multiple patents and publications in the field.
Follow Sasan Amini:
About Clear Labs: Clear Labs is a provider of a fully-automated sequencing platform for turnkey diagnostics.
Fabien Beckers
Founder & CEO of Arterys
Fabien Beckers is the CEO and co-founder of Arterys, a cloud/deep learning startup that is disrupting the medical imaging space and building image-based precision medicine tools. Fabien has led the growth of the company from four co-founders to a team of 34 today. Under his leadership, the company has become a pioneer in cloud-based medical imaging software, offering the first FDA-cleared end-to-end cloud infrastructure for medical imaging. They key advantages of the platform being automatic aggregation of real-world data and ability to scale and distribute the processing of increasingly large, complex datasets. Fabien’s vision for the company is to accelerate data-driven medicine by building precision medicine tools based on the consistent quantification of medical image features in combination with molecular, genomics and patient history data. Fabien holds a PhD in Quantum Physics from the University of Cambridge and a masters of business from Stanford University.
Follow Fabien Beckers:
About Arterys: Arterys is a medical imaging platform to deliver clinical AI products over the internet.
Chris Wheeler
Co-Founder & CEO of Diagnose Early
Follow Chris Wheeler:
About Diagnose Early, WISC Partners: Diagnose Early provides detection technologies for cancer, neurological, and infectious diseases.
Amit Vohra
Co-Founder, President & CEO of Promaxo
Promaxo is led by Dr. Amit Vohra who is a serial entrepreneur, business strategist and advisor to several healthcare and technology startups. Amit is a Partner in Advanced Biopharma Consulting, a management consultancy offering strategic business development and commercialization services in the life sciences space. He also serves as an advisor to Cricking, MedDx and HealthyX and a strategy consultant to Precision Biopsy and Weinberg Medical Physics. Prior to Promaxo, Amit was the CEO/President of Convergent Life Sciences wherein he took a MRI-US fusion product, for targeted laser ablation of soft tissue cancer, through FDA clearance within 18 months of Company formation. Previously, as VP of Strategy and Operations at Eigen, he led the development and successful commercialization of two class II medical devices in the prostate biopsy space. In 2009, Amit co-founded Navya Biomedical Technologies, a biotechnology company using proprietary polyhydroxy fullerenes (PHF) for non-invasive imaging and destruction of solid tumors. Amit has a Doctorate in Mechanical Engineering from University of Florida, and an Executive MBA (Fuqua Scholar) from Duke University’s Fuqua School of Business.
Follow Amit Vohra:
About 8chili, Neuro42, Promaxo, TriOcula Technologies: Promaxo is commercializing customer-centric MRI systems and robotic guidance tools for live diagnosis and treatment in a physician’s office.
Michael Bartholomew
Co-Founder, Inside Director & Chief Commercial Officer of Promaxo
Mr. Michael Bartholomew is the EVP and Chief Commercial Officer at Promaxo. He has broad therapeutic experience across nearly twenty diseases covering large and small molecules, medical devices and diagnostics. Michael manages the go to market strategy, voice of customer, partner relationships and tactical implementation relating to corporate infrastructure. Prior to Promaxo, Michael was a Principal at Porzio Life Sciences, as well as Vice President of Sales & Marketing for Dohmen Life Science Service, where he developed and launched several commercial initiatives achieving sustained sales growth. Before Dohmen, he served in various sales and brand leadership positions for Pfizer, Pharmacia and Baxter. Michael proudly served in the US Air Force as a decorated combat aviator, where he achieved the rank of Captain. He received his Masters of Science in Administration from Central Michigan University and his Bachelor of Arts in Economics from Indiana University.
Follow Michael Bartholomew:
About Neuro42, Promaxo: Promaxo is commercializing customer-centric MRI systems and robotic guidance tools for live diagnosis and treatment in a physician’s office.
Tim Sweeney
Co-Founder & CEO of Inflammatix
Tim Sweeney, MD, PhD is the co-Founder & CEO of Inflammatix, Inc., which focuses on using robust informatics and machine learning to derive novel HostDx™ diagnostics based on ‘reading’ patterns in the immune system. Inflammatix’s first tests are focused on diagnosing acute bacterial and viral infections and sepsis. The company is funded by Khosla Ventures, Stanford-StartX Fund and the U.S. government’s DARPA program. Tim Sweeney completed his MD and PhD at Duke University, after which he was a surgery resident at Stanford. While training as a surgeon, he became frustrated with the limitations of current diagnostic tools for infection. During his residency, he completed a postdoctorate MS in Biomedical Informatics, mentored by Dr. Purvesh Khatri. Together they designed the custom informatics algorithms for sifting through heterogeneous ‘big data,’ which formed the core technology on which Inflammatix is based.
Follow Tim Sweeney:
About Inflammatix: Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by reading the immune system.
Robin Berzin
Founder & CEO of Parsley Health
Robin Berzin, MD is the founder and CEO of Parsley Health, a primary care medicine provider with a data-driven, whole body approach. A summa cum laude graduate of the University of Pennsylvania, she completed medical school at Columbia University’s College of Physicians and Surgeons and trained in internal medicine at Mount Sinai Hospital in New York City. Dr. Berzin also trained with the Institute for Functional Medicine, where she acts as an advisor on digital technology. She speaks regularly for organizations including Stanford Medicine X, Health 2.0, Rock Health, Summit Series, and Further Future about how health care can be reinvented.
Follow Robin Berzin:
About Parsley Health: Parsley Health is redesigning primary care by integrating the latest in medical testing, technology and nutrition research.
Jenny Rooke
Founder & Managing Director of Genoa Ventures
Dr. Jenny Rooke has been deploying capital at the frontiers of life sciences innovation, with a penchant for technology-fueled solutions and category-defying opportunities. Jenny got her start in venture at Fidelity Biosciences, a Cambridge-based healthcare VC, during their Fund I formation. Jenny then brought her unique toolkit of genetics domain expertise, strategic business acumen, and venture investing to the Gates Foundation, where she deployed and managed over $250M in funding in genetic engineering, diagnostics, and synthetic biology. She also played a key role in establishing the foundation’s investing function. In 2014, Dr. Rooke began independently investing under the brand 5 Prime Ventures, financing her investments using what has become the largest life sciences syndicate on AngelList, and one of the highest-performing AngelList syndicates of any sector. Jenny founded Genoa Ventures in 2018, building on the 5 Prime Ventures track record, in order to scale a proven, differentiated investing strategy, to ensure continued access to the very best deals, and to maximize portfolio returns.
Follow Jenny Rooke:
About Genoa Ventures: Genoa Ventures is a venture capital firm that invests in early-stage life sciences technology companies.
Mark Kaganovich
Co-Founder & CEO of SolveBio
Mark Kaganovich is the Co-Founder & CEO at SolveBio.
Follow Mark Kaganovich:
About SolveBio: SolveBio deploys technology and on-demand expertise to drive precision medicine. We monitor, gather, and secure Genomic Intelligence.
Anthony Girand
CEO, Co-Founder of VoyagerMed
Anthony has over 15 years of experience as a Private Wealth advisor on Wall Street. He left Forbes Family Trust in 2014 to start VoyagerMed and has been spearheading the company’s digital operations ever since. Contact Anthony at anthony@voyagermed.com
Follow Anthony Girand:
About VoyagerMed: A medical tourism marketplace faciliating access to life changing medical innovations from trusted doctors around the world.
Struan Coleman
Chief Medical Adviser, Co-Founder of VoyagerMed
Struan Coleman MD, PhD, is a world-renowned, board-certified orthopedic surgeon specializing in hip preservation and sports medicine at Hospital for Special Surgery in New York City and the Vincera Institute in Philadelphia. Struan Coleman earned a medical degree from Columbia College of Physicians and Surgeons and holds a D.Phil in Microbiology from Oxford University, England. He completed both his residency in Orthopedic Surgery and a fellowship in Sports Medicine at the Hospital for Special Surgery. During his fellowship, Struan Coleman worked as an assistant physician for the New York Giants football team and is currently the Head Team Physician for the New York Mets baseball team. Struan Coleman focuses on the treatment and management of sports related injuries of the hip, knee, and shoulder, with a particular interest in hip arthroscopy and hip preservation. In his practice, he treats young, athletic patients with hip pathology; in addition, he has performed arthroscopic surgery on many high level athletes with hip problems, including NFL players from the Green Bay Packers, Oakland Raiders, and Washington Red Skins. Struan Coleman also combines his clinical practice with research relating to the fields of hip arthroscopy and sports medicine, and he has published numerous articles and written chapters in those fields. Struan Coleman holds numerous patents for technologies that are utilized by sports medicine physicians and surgeons. Most recently, he patented the technology behind the CyMedica QB1 Rehabilitation System, which is used to treat quadriceps atrophy. Struan Coleman is the founder of CyMedica Orthopedics and he is on the board of the company.
Follow Struan Coleman:
About CyMedica, New York Mets, VoyagerMed: A medical tourism marketplace faciliating access to life changing medical innovations from trusted doctors around the world.
Michael Cline
Co-Founder of Accolade
Michael Cline is the Founder and Chairman of Accolade.
Follow Michael Cline:
About Accolade, Accolade, Accretive, Accumen: Accolade features personalized health and benefits solutions that help to improve experience, outcomes, and healthcare cost for employers.
Philippe Leboulch
Founder & Co-Chair of Scientific Advisory Board of Bluebird Bio
Head of the Institute of Emerging Diseases and Innovative Therapies of CEA and INSERM; Professor of Medicine, University of Paris; and Visiting Professor, Harvard Philippe Leboulch is a scientific founder of bluebird bio. He serves as the co-chairman of its Scientific Advisory Board and leader of the LentiGlobin® project. He is a professor of medicine and cell biology at the University of Paris and visiting professor at Harvard Medical School. Philippe is also the director of the Institute of Emerging Diseases and Innovative Therapies of the CEA near Paris and director of an INSERM research unit. He maintains a research laboratory in the genetics division of the Brigham & Women’s Hospital at Harvard Medical School, where he previously served as a full-time faculty member for 15 years after a postdoctoral fellowship at MIT. Philippe is an expert in vectorology and hematopoietic gene therapy, with special emphasis on the beta-hemoglobinopathies. He has been published extensively in high-impact journals and is a regularly invited speaker at major international conferences. Philippe was a member of the Editorial Board of Blood, the Journal of the American Society of Hematology. He has served on major committees of the National Institutes of Health and the American Society of Gene Therapy. Philippe has received numerous NIH grant awards and prizes that include the Grand Prize Etancelin of the French National Academy of Sciences.
Follow Philippe Leboulch:
About Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Mark McKenna
Founder, President and CEO of Prometheus Biosciences
Mark McKenna currently works as President and Chief Executive Officer at Prometheus Biosciences. He previously worked at Bausch + Lomb as Senior Vice President and General Manager.
Follow Mark McKenna:
About Prometheus Biosciences: Prometheus Biosciences develops and commercializes pharmaceutical and diagnostic products to help physicians individualize patient care.
Martyn Gross
Co-Founder & CEO of Zerigo Health
Advisor at Cooler Heads Care & Chief Business Officer at Mindera.
Follow Martyn Gross:
About Dthera Sciences, MiNDERA Corporation, Zerigo Health: Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
Remo Moomiaie-Qajar M.D.
Co-Founder of Zerigo Health
Dr. Moomiaie-Qajar is a trained surgeon from Yale University with a long academic history of innovating technologies in medicine and translating them into commercially viable products. Dr. Moomiaie-Qajar has 15 years of experience incubating technologies from start-up or early stage level to exit. His background as an academic researcher, physician, and entrepreneur brings an unique trifecta of perspective and experience to Cytonus. He holds a number of US and International Patents and has successfully funded and launched a number of Life Science companies. He is the past CEO of Remo CRO, a full service CRO and Dr. Moomiaie-Qajar is an active member of a number of National Angel Investment Groups and manages a Life Science seed fund.
Follow Remo Moomiaie-Qajar M.D.:
About Remo Life Science, Zerigo Health: Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
Remo Qajar
Co-Founder of Zerigo Health
Remo Qajar is the Co-Founder and Chief Innovation Officer at Skylit Medical. Remo’s postgraduate career as an academic researcher and trained Surgeon at the Yale School of Medicine led him to invent a number of medical devices, from implantable respiratory diaphragms to orthopedic and wound care products, some of which have been spun-off into companies. Remo is the founder of InQMEDS LLC. an accelerator of growth for early stage life-science products.
Follow Remo Qajar:
About Zerigo Health: Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
Kyle Michelson
Founder & CEO of Getlabs
Kyle Michelson is the Founder and CEO of Getlabs. He is a former Founder of Streamup and Instameet.
Follow Kyle Michelson:
About Getlabs: Getlabs delivers healthcare to patients with in-person medical professionals.
Connor Landgraf
Co-Founder & CEO of Eko Health
Connor Landgraf is the co-founder and CEO of Eko.
Follow Connor Landgraf:
About Eko Health: Eko develops AI-powered digital tools to detect and monitor heart and lung disease
Jason Bellet
Co-Founder, Chief Strategy Officer, Board Member of Eko Health
Follow Jason Bellet:
About Eko Health: Eko develops AI-powered digital tools to detect and monitor heart and lung disease
Tyler Crouch
Co-Founder, VP of Mobile Engineering & Product Development of Eko Health
Follow Tyler Crouch:
About Eko Health: Eko develops AI-powered digital tools to detect and monitor heart and lung disease
James H. Bullard
Co-Founder and CTO of Pendulum Therapeutics
James Bullard is a Computational Biologist and Biostatistician with extensive experience in analyzing complex genomic systems. Prior to co-founding Whole Biome, Jim served as a Senior Staff Scientist at Pacific Biosciences. Jim, completed his Ph.D. in Biostatistics with a focus in Computational and Genomic Biology at the University of California, Berkeley and his B.A. in Computing and Information Systems at Northwestern University.
Follow James H. Bullard:
About Pendulum Therapeutics: Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
Colleen Cutcliffe
Co-Founder and CEO of Pendulum Therapeutics
Colleen Cutcliffe is the Co-Founder and CEO of Pendulum Therapeutics.
Follow Colleen Cutcliffe:
About American Diabetes Association, California Life Sciences Association, Pendulum Therapeutics: Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
John S. Eid
Co-Founder and CSO of Pendulum Therapeutics
John Eid is a Biophysicist who has led fundamental technology development for over a decade. His research areas include advanced microscopy, single molecule detection and analyses, automated data acquisition system development, biophysical system modeling, genome sequencing applications and bioinformatics. Prior to co-founding Whole Biome, John served as a Principle Scientist at Pacific Biosciences. He joined the company shortly after it was founded and created, developed and applied its core sequencing technology from its incipient stages through commercialization. John completed his postdoctoral research at the Roland Institute at Harvard University, his Ph.D. in Biophysics and Computation Biology at the University of Illinois, Urbana Champaign, and his B.S. in Applied and Engineering Physics from Cornell University.
Follow John S. Eid:
About Pendulum Therapeutics: Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
Benjamin Kruger
Co Founder of Sollis Health
Ben Kruger operates out of Vandewater’s Los Angeles office, sourcing and analyzing new business opportunities while managing preexisting investments within the company’s diverse portfolio. Ben contributes a majority of his time to Vandewater Media where he leads its Content and Creative team. Before joining Vandewater, Ben was the Creative Director of Jesta Digital. Ben has also contributed as a writer and producer for ABC Studios and Paramount Pictures. Kruger holds a bachelor’s degree in History from Brown University and is the recipient of a History Research Fellowship from St. Edmund Hall at Oxford University, UK.
Follow Benjamin Kruger:
About Sollis Health: Sollis Health offers 24/7 concierge medical centers that handle emergencies, everyday checkups, and everything in between.
Dr. Bernard Kruger
Founder of Sollis Health
Board-certified in Oncology and Internal Medicine and on faculty at Weill Cornell, Dr. Kruger has been serving the needs of his patients for more than 30 years from his office in Manhattan’s Upper East Side. As a pioneer of concierge medicine, Dr. Kruger has devoted his career to making the doctor–patient relationship as comfortable, reliable and easy as possible.
Follow Dr. Bernard Kruger:
About Sollis Health: Sollis Health offers 24/7 concierge medical centers that handle emergencies, everyday checkups, and everything in between.
Andrew Olanow
Founder of Sollis Health
A passionate advocate for improvements in the healthcare industry, Andrew has been a healthcare investor and analyst for more than 10 years at Generation IM, Morgan Stanley and Merrill Lynch. He has consulted for many health systems and advised multinational institutions toward more effective and efficient healthcare models. Andrew holds an MBA from London Business School and a BA from Columbia University.
Follow Andrew Olanow:
About Sollis Health: Sollis Health offers 24/7 concierge medical centers that handle emergencies, everyday checkups, and everything in between.
Jay Komarneni
Founder and Chair of Human Diagnosis Project
Jayanth Komarneni is the Founder & Chair of the Human Diagnosis Project (‘Human Dx’), a worldwide effort to map any human health problem to its possible diagnoses. By combining the collective intelligence of doctors with machine learning, Human Dx intends to enable more accurate, affordable, and accessible care for all. Human Dx has received clinical case contributions from thousands of medical professionals and trainees representing more than 60 countries, 400 institutions, and 40 specialties. Prior to Human Dx, Komarneni advised leadership at some of the world’s preeminent organizations while working at McKinsey & Company and Bain & Company. Komarneni’s work spanned healthcare stakeholders in the social, public and private sectors, including: governments, foundations, payers, providers, biotechnology companies, pharmaceutical companies, private equity firms, and hedge funds. After McKinsey and Bain, he helped launch, operate, and make investment decisions for a global alternative investment firm that has grown to billions in assets under management and remains active today. Komarneni also participated in Y Combinator, the world’s leading software accelerator. Komarneni completed five degree programs in six years at the University of Oxford and the University of Pennsylvania (Penn). As an undergraduate at Penn, he studied engineering, economics, math, and chemistry in the Jerome Fisher Management & Technology Program. Komarneni was then the first student accepted directly into the dual-degree Master of Biotechnology and Wharton MBA program. At Oxford, he earned an MSc in Global Health Science, a program led by Dr. Harold Jaffe, the former Director of the National Centers for Disease Control (CDC) for HIV, STD, and TB Prevention. Komarneni has been recognized as a Thouron Scholar, a Rhodes Scholarship finalist, and a Luce Scholarship recipient.
Follow Jay Komarneni:
About Human Diagnosis Project: Human Diagnosis Project is a worldwide effort to build an online system that maps the best steps to help any patient.
Ayub Khattak
Founder & CEO of Cue
Ayub Khattak is the CEO and founder at Cue.
Follow Ayub Khattak:
About Cue: Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep.
Maneesh Jain
CEO and Co-Founder of Mirvie
Maneesh Jain currently works as Chief Executive Officer and the Founder of Mirvie. He previously worked at Cirina (Grail) as CEO and President.
Follow Maneesh Jain:
About Mirvie: Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health.
Eric Xing
Founder, Executive Chairman, Chief Scientist of Petuum
Eric Xing is a professor at Carnegie Mellon University and researcher in machine learning, computational biology, and statistical methodology.
Follow Eric Xing:
About Carnegie Mellon University, Petuum: Petuum, Inc. is building a platform that serves the full spectrum of Artificial Intelligence
Qirong Ho
Founder and Chief Technology Officer of Petuum
Qirong Ho is vice president of technology at Petuum, Inc., an adjunct assistant professor at the Singapore Management University School of Information Systems, and a former principal investigator at A*STAR’s Institute for Infocomm Research. Qirong’s research focuses on distributed cluster software systems for machine learning at big data and big model scales, with a view toward theoretical correctness and performance guarantees, as well as practical needs like robustness, programmability, and usability. Qirong also works on statistical models for large-scale network analysis and social media, including latent space models for visualization, community detection, user personalization, and interest prediction. He is a recipient of the Singapore A*STAR National Science Search Undergraduate and PhD fellowships and the KDD 2015 Doctoral Dissertation Award (runner up).
Follow Qirong Ho:
About Petuum, Singapore Management University: Petuum, Inc. is building a platform that serves the full spectrum of Artificial Intelligence
David Wetherell
Founder & Managing Director of Biomark Capital
Follow David Wetherell:
About Biomark Capital: Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies.
Giuliano Senese
Founder & CEO of DX Medical Solutions
Follow Giuliano Senese:
About DX Medical Solutions: Medical Technology Startup
Paul Hindrichs
Co-Founder, CTO of Conventus Orthopaedics
Paul Hindrichs is a veteran business leader and innovator with more than 20 years of medical device experience. He has served in various management capacities during his career, including positions with several other start-up and early stage medical device companies. Prior to founding Conventus, he worked for St. Jude Medical (SJM), Vascular Science, Inc., Optical Sensors, Inc., and Schneider USA (Pfizer). Most recently, he was responsible for the Structural Heart Business and Cardiac Technologies Group at SJM. Mr. Hindrichs earned a Bachelor of Science in Mechanical Engineering from the University of Minnesota and is a named inventor on 20 issued and 22 pending patent applications.
Follow Paul Hindrichs:
About Conventus Orthopaedics, Endogenex: Conventus Orthopaedics is a provider of a range of orthopedic and sports medicine services.
Giulio Ruffini
President, CSO and co-founder of Neuroelectrics
Dr. Giulio Ruffini is the CEO and CTO of Starlab and the president and CSO of Neuroelectrics. He obtained a BA in Mathematics & Physics from Berkeley and a PhD in theoretical physics from UC Davis/LANL in 1995. In 2000 he founded Starlab to transform science into high-impact technologies.
12 years later he founded Neuroelectrics, a company which combines high-precision multichannel stimulation technologies with advanced biophysical and neuro-computational models.
For the past 15 years, Giulio has been developing technology for and researching the use of non-invasive brain monitoring and brain stimulation techniques, with a focus on EEG and transcranial current stimulation. His paper on brain-to-brain telepathy communication was the top 10 most shared papers of 2014. He is currently leading or involved in several European programs such as Galvani ERC Synergy, STIPED or Neurotwin.
Follow Giulio Ruffini:
About Neuroelectrics: Neuroelectrics is a digital brain health company that diagnoses and treats brain disorders with personalized neuromodulation, and improves overall brain health.
Alex Dresner
Co-Founder & Co-CEO of Imagen Technologies
Alex is a Co-Founder and the Co-CEO of Imagen. Prior to co-founding Imagen, Alex worked as the Head of the Hospital for Special Surgery’s Value Analytics and Management Office. Alex began his career at Bridgewater Associates where he was a member of the Core Management Team. Alex received his bachelor’s degree from the London School of Economics.
Follow Alex Dresner:
About Imagen Technologies: Powering the future of primary care
Thomas Schuetz
Co-Founder of Audentes Therapeutics
Dr. Schuetz, M.D., Ph.D., is the co-founder of Audentes Therapeutics and has served as a member of the board of directors since July 2013. Dr. Schuetz also provided consulting services to Audentes from July 2012 to June 2013. Dr. Schuetz is currently the Chief Executive Officer of Compass Therapeutics, LLC. Previously, Dr. Schuetz was a Venture Partner at OrbiMed. Dr. Schuetz served as the Chief Medical Officer of Therion Biologics Corporation and the Vice President of Clinical Affairs at Transkaryotic Therapies, Inc. (now Shire Pharmaceuticals, Inc.). Dr. Schuetz has also served as the Chief Medical Resident at Massachusetts General Hospital and completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Schuetz also serves on the board of directors of Relypsa, Inc. and Glypharma, Inc. Dr. Schuetz holds a B.S. in chemistry from Xavier University, an M.D. from Harvard Medical School and a Ph.D. in genetics from Harvard University. Dr. Schuetz is Board Certified in Medical Oncology.
Follow Thomas Schuetz:
About Audentes Therapeutics, Compass Therapeutics, Inc.: Audentes is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.
Eric Schadt
CEO & Founder of Sema4
Eric Schadt is Chief Scientific Officer of Pacific Biosciences and Director of the Institute for Genomics and Multiscale Biology and Chair of the Department of Genetics and Genomics Sciences at The Mount Sinai Medical Center. He oversees the scientific strategy for Pacific Biosciences, including creating the vision for next-generation applications of the company’s technology, contributing to the evolution of Pacific Biosciences’ transformative sequencing technology, and playing a key role in the company’s strategic relationships. At Mount Sinai, Eric is creating a world-class data analytic center where researchers can query and learn from data using cutting-edge technologies like next generation sequencing to create disease models and ultimately help develop and improve the diagnosis and treatment of patients. He is also a founding member of Sage Bionetworks, an open-access genomics initiative designed to build and support databases and an accessible platform for creating innovative dynamic disease models. Eric Schadt joined Pacific Biosciences in May 2009 from Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. in Seattle, where he was Executive Scientific Director of Genetics. Eric Schadt’s work at Rosetta involved the generation and integration of very large-scale sequence variation, molecular profiling, and clinical data in disease populations to construct the molecular networks that define disease states and link molecular biology to physiology in ways that can impact clinical medicine. Eric Schadt has contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes and obesity, which have been widely published in leading scientific journals. His research has provided novel insights into what is needed to master diverse, large-scale data collected on normal and disease populations in order to elucidate the complexity of disease and make more informed decisions in the drug discovery arena. Prior to joining Rosetta, Eric Schadt was a senior research scientist at Roche Bioscience. He received his BA in applied mathematics and computer science from California Polytechnic State University, his MA in pure mathematics from UCLA, and his Ph.D. in bio-mathematics from UCLA.
Follow Eric Schadt:
About Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai, Sage Bionetworks, Sema4: Sema4 uses artificial intelligence and machine learning to analyze patient data to provide insights to transform the practice of medicine.
Christopher K. Zarins
Founder & Senior Advisor for Clinical Affairs of HeartFlow
Follow Christopher K. Zarins:
About HeartFlow: HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease.
Charles A. Taylor
Founder and Chief Technology Officer of HeartFlow
Charles Taylor is a co-founder, Chief Technology Officer (CTO), and member of the Board of Directors of HeartFlow Inc. Previously, he was an Associate Professor in the Department of Bioengineering and Surgery at Stanford University with courtesy faculty appointments in the Departments of Mechanical Engineering and Radiology. He is internationally recognized for the development of computer modeling and imaging techniques for cardiovascular disease research, device design and treatment planning. He received his B.S. degree in Mechanical Engineering, M.S. degree in Mechanical Engineering and M.S. degree in Mathematics from Rensselaer Polytechnic Institute and a Ph.D. in Mechanical Engineering from Stanford University.
Follow Charles A. Taylor:
About HeartFlow: HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease.
Jay Bradner
Co-Founder of C4 Therapeutics
Jay Bradner, MD. President, Novartis Institutes for Biomedical Research, effective March 1, 2016. Former Associate Professor, Harvard Medical School. Co-founder of SHAPE Pharmaceuticals, Acetylon Pharmaceuticals, Tensha Therapeutics, and Syros Pharmaceuticals. First to accomplish an all-chemical strategy for target-specific protein degradation (Science, 2015).
Follow Jay Bradner:
About Acetylon Pharmaceuticals, Broad Institute, C4 Therapeutics, Novartis Institutes, Shape Pharmaceuticals, Syros Pharmaceuticals, Tensha Therapeutics: C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
Guangqiang Jiang
Co-Founder & Chief Technology Officer of Axonics Modulation Technologies
Dr. Jiang is a seasoned technical executive with a 15-year track record of developing complex, implantable Class III medical devices. He was previously VP of R&D at the Alfred Mann Foundation. Dr Jiang was elected to the American Institute for Medical and Biological Engineering (AIMBE)’s College of Fellows and served as Principal Investigator on several government contracts. Dr Jiang holds a Ph.D. in Biomedical Engineering from the University of Southern California.
Follow Guangqiang Jiang:
About Axonics Modulation Technologies: Axonics Modulation Technologies is a pre-revenue company developing novel implantable neuromodulation.
Renee Dua
Founder and Advisor of Heal
Dr. Dua is board certified in nephrology, hypertension, and internal medicine and served as Chief of Medicine at Valley Presbyterian and Simi Valley Hospitals. She is now the Founder and Advisor of Heal. She completed her BS in Biochemistry at UC San Diego, her MD at Rosalind Franklin University, her residency at UCLA, and her fellowship in nephrology at USC. Renee and her husband are enjoying the travails of being parents to a rambunctious 1-year-old boy.
Follow Renee Dua:
About Burrito Labs, Heal: Heal is an in-home primary care practice that offers modern doctor house calls, one-touch telemedicine and remote monitoring for seniors.
Prashant Warier
Co-Founder & CEO of Qure AI
Prashant Warier is a Co-Founder and the Chief Executive Officer at Qure.ai.
Follow Prashant Warier:
About Fractal Analytics, Qure AI: build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients
Srinivasa Nagalla
Founder , President & CEO of DiabetOmics
Dr. Nagalla is the principal founder and chief executive officer of DiabetOmics. He was previously founder and CEO of ProteoGenix, Inc., a successful innovator in maternal-fetal health diagnostics, which was acquired by Hologic, Inc. (HOLX) in 2010. Before founding ProteoGenix, Dr. Nagalla was Associate Professor of pediatrics at Oregon Health & Science University. He is the lead inventor on several key patents on biomarkers for clinical diagnostics, and has previously served on National Institutes of Health-sponsored national consortiums of biotechnology, genomics, and proteomics. Dr. Nagalla has 20+ years of broad multi-disciplinary experience in clinical medicine, biotechnology, and commercialization. Dr. Nagalla received his M.D. from the All-India Institute of Medical Sciences, New Delhi, and post-doctoral training at Harvard University and Oregon Health & Science University.
Follow Srinivasa Nagalla:
About DiabetOmics: DiabetOmics is a medical diagnostics company that provides non-invasive assessment and management of personalized health and diabetes risk.
Paturi V. Rao
Co-Founder and Director of DiabetOmics
Dr. Rao is co-founder and director for DiabetOmics operations in India and Asia. Dr. Rao is Professor and Chief of Endocrinology at Nizam’s Institute of Medical Sciences University in Hyderabad, India. Dr. Rao served as Secretary of Research Society for the Study of Diabetes in India (RSSDI) from 1993-2007. RSSDI is the largest diabetes care provider’s organization in Asia, with more than 7000 member diabetologists. Dr. Rao has served as principal investigator on several key international clinical studies in diabetes, including ORIGIN, DREAM, and several phase-II and phase-III clinical trials for Novo Nordisk, Eli Lilly, Aventis, Merck Scharpe & Dohme, Novartis, and Johnson & Johnson. Dr. Rao serves on the advisory committees of the Indian Council of Medical Research, Department of Science & Technology, and several pharmaceutical companies.
Follow Paturi V. Rao:
About DiabetOmics: DiabetOmics is a medical diagnostics company that provides non-invasive assessment and management of personalized health and diabetes risk.
Charles Roberts
Co-Founder , Vice President and Chief Science Officer of DiabetOmics
Dr. Roberts is co-founder and chief science officer since 2008. Dr. Roberts is a molecular endocrinologist with over 25 years of experience in diabetes research, is an internationally recognized expert on insulin action, and has authored over 250 scientific papers and review articles. Dr. Roberts is also a co-inventor on various patents on therapeutics and biomarkers for clinical diagnostics, and serves on numerous review panels for the National Institutes of Health and the editorial boards of several major biomedical research journals. From 1984-1994, he was a Senior Investigator in the Diabetes Branch of the National Institutes of Health in Bethesda, MD, and subsequently Professor and Associate Chair for Research in the Department of Pediatrics and Professor of Medicine at Oregon Health & Science University.
Follow Charles Roberts:
About DiabetOmics: DiabetOmics is a medical diagnostics company that provides non-invasive assessment and management of personalized health and diabetes risk.
Ron Zwanziger
Co-Founder, Chief Executive Officer, Chairman, and Director of LumiraDx
Ron Zwanziger, a strategic visionary and entrepreneur, is the CEO of LumiraDx, which he co-founded in 2014. He previously founded and led numerous successful diagnostic firms, including Alere, Inverness Medical Technology (which was acquired by Johnson & Johnson in 2001), and MediSense, the first company to introduce an electrochemical glucose sector. He currently serves on the Board of Directors of several private companies.
Follow Ron Zwanziger:
About LumiraDx: LumiraDx is a healthcare company that manufactures a diagnostic platform to support a menu of tests with lab comparable performance.
Sumit Nagpal
Co-Founder of LumiraDx
Follow Sumit Nagpal:
About Cherish Health, HIMSS, HIMSS, LumiraDx: LumiraDx is a healthcare company that manufactures a diagnostic platform to support a menu of tests with lab comparable performance.
Stephen Cary
Founder of Omniox
Stephen Cary is the co-founder and CEO of Omniox, and co-inventor of the H-NOX technology. Stephen identified H-NOX as a potential therapeutic platform while working at the University of California, Berkeley. He secured the first financial support for Omniox by winning the inaugural Rogers Family Foundation “Bridging the Gap” Award at QB3. Subsequently, Stephen and his team obtained multiple NIH SBIR awards and a Wellcome Trust Translation Award to build Omniox’ operations and enable development of the H-NOX platform. Prior to launching Omniox, Stephen worked at Genentech in Market Strategy, and before that in Immunology Research. He participated extensively in early stage development projects, concentrating on strategic processes of transitioning therapeutic candidates from late-stage research to early development, and provided market and endpoint inputs into design of clinical trials. Stephen obtained his PhD in Biological Chemistry with Michael Marletta at the University of Michigan, and his Bachelor of Science degree in Molecular Biophysics & Biochemistry at Yale University.
Follow Stephen Cary:
About Omniox: Omniox, a biotechnology company, commercializes technologies used in identifying and treating cancer, cardiovascular disease and trauma.
Jeffrey Port
Co-Founder & Chairman of Angiocrine Bioscience
Jeffrey Port is the Founder of Angiocrine Bioscience, Inc.
Follow Jeffrey Port:
About Angiocrine Bioscience, RF Surgical Systems, TMRW Life Sciences, Weill Cornell Medicine, Weill Cornell Medicine: Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
John Klacking
Co-Founder of Angiocrine Bioscience
John Klacking is the Founder of Angiocrine Bioscience.
Follow John Klacking:
About Angiocrine Bioscience: Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
Shahin Rafii
Scientific Founder of Angiocrine Bioscience
Shahin Rafii is the Founder of Angiocrine Bioscience.
Follow Shahin Rafii:
About Angiocrine Bioscience: Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
